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INTRODUCTION
Pulmonary tuberculosis (TB) is an infectious disease causing high morbidity 
and mortality throughout the world.[1-5] In 2015, reports showed an estimated 
10.4 million cases of tuberculosis globally, including 1.2 million (11%) people 
living with Human Immunodeficiency Virus (HIV). Recent reports showed 
that 57% of TB among people living with HIV was not promptly diagnosed or 
treated, resulting in 390,000 tuberculosis-related deaths in 2015.[6, 7]
HIV infection increases the risk of TB infection [8, 9] by 26 to 36 times.[10,11] TB 
causes about a third of HIV-related deaths.[4,6] Mycobacterium tuberculosis is 
defined as multidrug-resistant when it becomes resistant to first-line drugs as 
isoniazid and rifampin. This accounts for 5% of all TB cases globally.[12,13] The 
World Health Organization (WHO) endorsed the Gene Xpert MTB/RIF for 
use in countries where TB is endemic and declared it a major milestone for 
global TB diagnosis in December 2010.[14]
In view of paucity of information about MDR-Tb in our locality, this study 
was carried out to determine the frequency among HIV sero-positive and sero-
negative populations
METHOD
Selection of subjects and specimen collection
The study was carried out between June 2017 and May 2018 in the chest clinic 
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Introduction: Multiple-drug resistant tuberculosis (MDR-Tb) has become a global 
issue especially in many African countries.  Regular studies are needed to ascertain 
its early detection and elimination in the endemic regions in order to reduce the 
morbidity and mortality rates 
Objective: To assess the frequency of MDR-Tb among HIV sero-positive and sero-
negative populations in Ilorin, North-Central Nigeria. 
Method: Sputum samples were collected from 1,601 subjects provisionally diagnosed 
with pulmonary tuberculosis (TB) at Sobi Specialist Hospital, Ilorin-Nigeria. 
Inclusion criteria were based on a cough for at least three weeks with no response 
to antibiotics treatment or when the chest Xray indicated TB infection. From each 
patient three specimens were obtained for Ziehl Neelsen staining and 4ml of blood 
were collected for HIV antibody testing. 
Results: The frequency of Acid Fast Bacilli (AFB) positive cases was 10.86% while 
0.72% MDR-Tb and 3.2% concurrent infection with Mycobacterium tuberculosis 
and HIV were documented. Statistically, no significant association between age and 
MDR-Tb (X2=0.6731, P>0.05) was found. 
Conclusion: The study revealed 10.86% of AFB positive cases, 0.74% MDR-Tb 
cases and 3.2% concurrent infection between Mycobacterium tuberculosis and HIV. 
We therefore recommend aggressive and effective control measures to prevent further 
transmission of MDR-Tb between patients and health care workers while increased 
access to ART for HIV infected MDR-TB patients is also suggested.
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of the Specialist Hospital Ilorin, north -central Nigeria 
on sputum collected from 1,610 patients provisionally 
diagnosed with pulmonary TB. Ethical approval was 
obtained from Ethical and Animal Care Committee of the 
School of Basic Medical Sciences, Kwara State University. 
Informed consent of the subjects and the parents of 
children was obtained.
A cross-sectional simple random method was employed. 
Inclusion criteria were based on a cough for at least three 
weeks with no response to antibiotics or when the chest 
Xray indicated TB infection.  
Three specimens were obtained per subject. The first 
specimen was produced on the first contact, the second 
produced early morning following the first day at home 
while the third was produced at the clinic. Four milliliters 
of blood were collected from each subject for HIV 
antibody testing.  
Laboratory analysis of specimens.
Each sputum specimen was treated with a mixture 
of sodium hypochlorite and sodium hydroxide for 
decontamination before analysis. Smears were made 
from the sediment of the specimens and stained by Ziehl 
Neelsen techniques and examined for Acid-Fast Bacilli.
Assessment for multiple drug resistance was based on the 
use of the Gene Xpert machine which is an automatic 
sputum processor by real time amplification. The process 
was repeated for all the specimens and only the concordant 
results were considered in this study.
Commercial Determine test strip (Global source, Shenyang 
LTH Tech, China) was employed for qualitative detection 
of HIV antibodies. Each test strip was removed from the 
foil, dipped in the serum for 30 seconds and allowed for 5 
minutes on the work bench for the serum to flow through 
control and test columns. Appearance of two pinkish lines 
in the strip within 5 minutes was an indication of HIV 
positive while appearance of a single line at the control 
column was an indication of negative HIV serum.
Statistical analysis
Data were analyzed using SPSS version 23 software 
(SPSS Inc. USA). The Chi Square test was used to assess 
the distribution of MDR-Tb and the frequency of co-
infection between AFB and HIV infection.
RESULTS
Frequency of Multiple Drug Resistance and co-infection 
of AFB and HIV with respect to age is shown in Table 
1. Out of 1,610 subjects examined, no case of  MDR-Tb 
was reported among age  groups of 15-29 years and 30-
44 years while 1.10% and 8.0% MDR tuberculosis were 
documented in age groups of 45-59 years and 60 years and 
above respectively. Chi-Square test showed no significant 
association between age and MDR-Tb (X2=0.6731, 
P>0.05).  The highest rate (4.2%) of concurrent infection 
was reported within the age group 30-44 years while no 
case of co-infection was recorded among those aged 60-
72 years. Statistically significant positive correlation was 
recorded between co-infection (of AFB and HIV) and age 
(r = 4.9210, P<0.05). 
Figure 1 shows that a higher rate of TB was recorded 
among the male subjects (n=98, 6.1%) than among 
females (n=75, 4.7 %). Conversely, a higher rate of HIV 
infection was recorded for females (n=36, 2.2 %) than the 
males (n=28, 1.7 %).  Our findings also revealed a higher 
rate (3.45%) of co-infection among females than in males 
with 3.10%.  Out of 175 AFB positive cases recorded, 47 
of them were also infected with HIV representing 26.90% 
of the AFB positive cases. 
Figure 2 shows the frequency of MDR-Tb in relation to 
HIV status. Out of 62 subjects tested positive for AFB 
with unknown HIV Status, six (9.6%) were MDR. Also, 
out of 63 HIV sero-positive cases living with TB, 6 (9.5%) 
were MDR resistant while no case of MDR was recorded 
among 50 HIV sero-negative subjects with tuberculosis.
Occurrence of co-infection of AFB and HIV with respect 
to marital status is as shown in Table 2. The results showed 
no case of co-infection among the widows whereas 2.98% 
and 0.90% of the co-infections were documented among 
single and married subjects respectively. Chi-square test 
showed no significant difference in the rate of co-infection 
with respect to marital status (X2=0.9337, P>0.05).






AFB + HIV   Co-infection   
    n (%)    
15-29             575 64 (11.13) 0(0.0) 28(4.9) 20 (3.4)
30-44              571 83(14.53) 0(0.0) 27(4.7) 24(4.2)
45-59              364 20(5.49 ) 4(1.10) 4(1.10) 8(2.2)
60-74              100 8 (8.00) 8(8.00) 4(4.0) 0( 0.00)
Total 1610  175 (10.86) 12(0.72) 63(3.91) 52(3.2)
Table 1. Frequency of Multiple Drug Resistance and co-infection of AFB and HIV according to age
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DISCUSSION
This study reveals 0.74% prevalence rate of MDR-Tb 
while 3.2% of co-infection with Mycobacterium tuberculosis 
and HIV was documented. The frequency of AFB positive 
cases was 10.86%. This finding differs from the result of a 
previous study[15] in which a 22% prevalence rate was found 
in the south-eastern part of the same country. Our sample 
size was larger and may explain this difference. Out of the 
175 AFB positive cases recorded, only 12 cases were MDR 
positive representing 4.0 % of the AFB positive cases and 
0.74% of the entire sampled population. Coincidentally, 
all the cases of MDR were documented among the HIV 
sero-positive population while none was reported among 
their sero-negative counterparts. The finding is similar to 
a previous WHO report.[5] 
The MDR result in the present study is however at variance 
with the 3.6% reported by Okorie et al.[15]  The difference 
could be attributed to the automated machine employed 
in this study while a manual technique was used by the 
previous authors. This requires further investigation.
Assessing the frequency of AFB positive cases with respect 
to age, the highest rate (14.53%) was recorded within the 
age group 30-44 years, implying that this age group was 
more vulnerable to Mycobacterium tuberculosis infection. 
However, there was no record of MDR-Tb among this 
age group whereas 8.0% was recorded among subjects of 
60 years and above. The reason for higher MDR among 
the older age group may be attributed to lower immunity 
with advancing age. Our finding differs from a previous 
study [8] where the highest rate was reported within 
the age of 50 years and above.  Chi-Square test showed 
no significant association between age and MDR-Tb 
(X2=0.6731, P>0.05) and between gender and MDR-Tb, 
(X2 = 0.912, P>0.05).
Our study showed no case of co-infection with HIV and 
AFB among the widows while 2.98% and 0.90% co-
infection was documented among the single and married 
subjects respectively. The reason for this could probably 
be due to a lower exposure by the widows to both 
infections as against single and married subjects. Also, 
non-uniformity of the specimens collected in the present 
study could probably be the cause of the variation.
Statistically, our findings showed a positive correlation 
between AFB and HIV prevalence in relation to age 
(r =4.9210, P <0.05). This observation implies that with 
Marital Status No examined AFB positive
n (%)
HIV positive                  
n (%)
AFB + HIV Co-infection    
 n (%)  
Single 436 43 (9.86) 20 ( 4.58) 13 (2.98)
Married 1035 132 (14.00) 43(4.15) 10 (0.90)
Widow/Divorced 139 0 ( 0.00) 0 (0.00) 0 (0.00)
Total 1610 175 (10.86) 63 ( 3.91) 23 (1.43)
Table 2. Concurrent infection of AFB and HIV in relation to marital status.
Figure 1. Distribution of AFB and HIV by gender Figure 2. Prevalence of MDR tuberculosis in relation to HIV status
South Sudan Medical Journal Vol 12. No 3 August 2019 96
ORIGINAL ARTICLE
the rate of Mycobacterium tuberculosis infection, the 
frequency of HIV in the study area may be predicted in a 
model investigation.
CONCLUSION
This study revealed 10.86% of AFB positive cases, 0.74% 
MDR-Tb and 3.2% concurrent infection between 
Mycobacterium tuberculosis and HIV. We therefore 
recommend aggressive and effective control measures to 
prevent further transmission of MDR-Tb between patients 
and health care workers while increased access to ART for 
HIV infected MDR-TB patients is also suggested. Further 
studies that may lead to the discovery of new molecular 
markers are germane for prompt diagnosis and control of 
MDR-Tb.
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